Cargando…

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer

Introduction: Oncogenic activation of ERG resulting from TMPRSS2-ERG gene fusion is a key molecular genetic alteration in prostate cancer (CaP). The frequency of ERG fusion is variable by race; however, there are limited data available on germline polymorphisms associating with ERG fusion status. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohaar, Indu, Li, Qiyuan, Chen, Yongmei, Ravindranath, Lakshmi, Young, Denise, Ali, Amina, Sesterhenn, Isabell A., Rosner, Inger L., Cullen, Jennifer, Srivastava, Shiv, Freedman, Matthew, Petrovics, Gyorgy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170497/ https://www.ncbi.nlm.nih.gov/pubmed/32341752 http://dx.doi.org/10.18632/oncotarget.27534

Ejemplares similares

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence
por: Yan, Wusheng, et al.
Publicado: (2019)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population
por: Petrovics, Gyorgy, et al.
Publicado: (2018)

Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes
por: Kohaar, Indu, et al.
Publicado: (2022)

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag
por: Rastogi, Anshu, et al.
Publicado: (2016)

A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
por: Kohaar, Indu, et al.
Publicado: (2019)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India
por: Rawal, Sudhir, et al.
Publicado: (2013)

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men
por: Duncan, Allison, et al.
Publicado: (2023)

Oncogenic activation of ERG: A predominant mechanism in prostate cancer
por: Sreenath, Taduru L, et al.
Publicado: (2011)

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2014)

Prostate cancer marker panel with single cell sensitivity in urine
por: Nickens, Kristen P., et al.
Publicado: (2015)

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2019)

ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men
por: Baohong, Jiang, et al.
Publicado: (2019)

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men
por: Petrovics, Gyorgy, et al.
Publicado: (2015)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression
por: Gesztes, William, et al.
Publicado: (2022)

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017)

TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation
por: Casey, Orla M., et al.
Publicado: (2012)

Biomarkers of Aggressive Prostate Cancer at Diagnosis
por: Boehm, Brock E., et al.
Publicado: (2023)

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1
por: Kumar, Parameet, et al.
Publicado: (2016)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression
por: Gao, Yuqian, et al.
Publicado: (2020)

Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression
por: Yin, Lihong, et al.
Publicado: (2011)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer
por: Kiebish, Michael A., et al.
Publicado: (2020)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody
por: Mohamed, Ahmed A., et al.
Publicado: (2010)

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
por: Nam, R K, et al.
Publicado: (2007)

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN
por: Li, Hua, et al.
Publicado: (2015)

Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG
por: Giannareas, Nikolaos, et al.
Publicado: (2022)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
por: Semaan, Louie, et al.
Publicado: (2019)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2021)

Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations
por: Pascal, Laura E, et al.
Publicado: (2016)

A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants
por: Lu, Qing, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ggl9akh46m60sqt7co866cleem